Hi-Tech Pharmaceuticals, Inc. v. Cohen

277 F. Supp. 3d 236
District Court, D. Massachusetts·Decided October 27, 2016·No. CIVIL ACTION NO. 16-10660-WGY·Published·Cited by 9 cases

Opinion

MEMORANDUM OF DECISION

YOUNG, D.J.

I. INTRODUCTION

This action involves claims by Hi-Tech Pharmaceuticals, Inc. (“Hi-Tech”) against Pieter A. Cohen (“Cohen”) for libel, slander, product disparagement, and violation of Massachusetts General Laws, chapter 93A (“chapter 93A”). Hi-Tech’s claims [241]*241arise out of statements Cohen made in an article and in media appearances in connection therewith concerning an ingredient in particular nutritional supplements manufactured and distributed by Hi-Tech. After the Court denied Cohen’s motions to dismiss the action, the parties cross-moved for summary judgment, with Cohen requesting judgment as matter of law on all claims and Hi-Tech seeking partial summary judgment. On October 5, 2016, the Court entered an order granting in part and denying in part Cohen’s motion, and denying Hi-Tech’s motion. It now explains its reasoning for doing so.

A. Factual Background

Hi-Tech is a pharmaceutical company that manufactures, distributes, and sells dietary supplements. Pl.’s Statement Undisputed Material Facts Pursuant Local Civil Rule 56.1 (“Pl.’s Statement Facts”) ¶ 1, ECF No, 70. Cohen, an internist and professor of medicine, id. ¶ 2, is the first author of an article entitled “An amphetamine isomer whose efficacy and safety in humans has never been studied, B-methyl-phenylethylamine (BMPEA), is found in multiple dietary supplements” (the “Article”), id. ¶ 7; Def., Pieter A. Cohen’s, Statement Facts Supp. Mot. Summ. J. (“Def.’s Statement Facts”) ¶ 5, ECF No. 61. The Article was published in Drug Testing and Analysis, a peer-reviewed journal, in April 2015. Def.’s Statement Facts ¶5; PL’s Statement Facts ¶ 7. It identifies six Hi-Tech supplements whose labels indicate that they contain “Acacia rigidula” and reports that those supplements contain a synthetic substance called BMPEA, even though, according to the Article, “there is no scientific evidence that BMPEA has ever been extracted from Acacia rigidu-la[,]” Def.’s Mem. Supp. Special Mot. Dismiss Pl.s’ Compl. Pursuant Mass. Gen. Laws ch. 231, § 59H, Ex. 2 (“Article”) 5, ECF No. 14-2. The Article goes on to state that “BMPEA’s effect on human health is entirely unknown” and that it “is not a legitimate supplement ingredient.” Article 6. Cohen stated that his conclusions were based on his review of various scientific articles and discussions with scientists, Def.’s Statement Facts ¶¶ 53-54, though the precise scope of Cohen’s research and the sources of which he was aware at the time of publication are disputed, see PL’s Resp. Def. Pieter A. Cohen’s Statement Facts Supp. Mot. Summ. J. ¶¶ 53-54, ECF No. 68; Def.’s Resp. PL’s Statement Material Facts Pursuant Local Civil Rule 56.1, Supp. PL’s Mot. Partial Summ. J. ¶ 36, ECF No. 72.

The Article calls on the Food and Drug Administration (“FDA”) to ensure supplements containing BMPEA are pulled from the market and urges manufacturers to recall, and consumers to avoid, BMPEA-containing products. Def.’s ■ Statement Facts ¶¶ 9-10; Article 6. Following the publication of the Article, Cohen spoke about supplements containing BMPEA in various media appearances, PL’s Statement Facts ¶¶ 9-11, stating, inter alia, that various supplements purportedly containing Acacia rigidula instead contain an untested “designer stimulant called BMPEA” that “is in a sense, being tested on buyers,” id. 111.

Hi-Tech issued a press release refuting Cohen’s contentions. Def.’s Statement Facts ¶ 23. Upon receiving a letter from the FDA stating that Hi-Tech’s labeling of its BMPEA-containing products is in violation of federal law and requesting that it take appropriate action, id. ¶20, Hi-Tech issued an additional press release objecting to the FDA’s letter, id. ¶ 21.

Hi-Tech claims that it has suffered economic harm as a result of Cohen’s statements, which it maintains are false, in the [242]*242form of lost customers, revenue, and sales contracts. Pl.’s Statement Facts ¶ 87.

B. Procedural History

Hi-Tech initiated this action on April 5, 2016. Compl., ECF No. 1. Cohen filed a timely motion to dismiss for failure to state a claim, Def., Pieter A. Cohen’s, Mot. Dismiss Compl., ECF No. 15, as well as a special motion to dismiss pursuant to the Massachusetts “anti-SLAPP”1 statute, Mass. Gen. Laws chapter 23, § 59H, Def.’s Special Mot. Dismiss Pl.’s Compl. Pursuant Mass. Gen. Laws ch. 231, § 59H, ECF No. 13. The Court denied these motions from the bench. Elec. Clerk’s Notes, ECF No. 40. The parties submitted further briefing on the anti-SLAPP issue, Def.’s Suppl. Br. Regarding Seventh Amendment Right Jury Trial and Mass. Gen. Laws ch. 231, § 59H (“Def.’s Suppl. Mem.”), ECF No. 47; PL’s Mem. Opp’n .Def.’s Mot. Reconsider, ECF No. 48, with Cohen requesting that this Court revise its earlier order denying Cohen’s special .motion to dismiss, Def.’s Suppl. Mem. 1. The Court declined to alter its ruling and issued a memorandum of decision setting forth its analysis of the anti-SLAPP issue.2 Elec. Clerk’s Notes, ECF No. 64; Mem. Decision, ECF No. 66.

The parties filed cross-motions for summary judgment on September 9, 2016. PL’s Mot. Partial Summ. J., ECF No. 56; Def.’s, Pieter A. Cohen, M.D., Mot. Summ. J., ECF No. 59. 'Cohen sought summary judgment on each of' Hi-Tech’s claims, Mem. Def., Pieter A. Cohen, Supp. Mot.-Summ. J. (“Def.’s Mem.”) 1, ECF No. 60, while Hi-Tech requested judgment as matter of law on a single issue, Br.’ Supp. PL Hi-Tech’s Mot. Partial Summ. J. (“PL’s Mem.”) 1, ECF No. 57. The Court- heard arguments on the parties’ summary judgment motions on September 29, 2016. Elec. Clerk’s Notes, ECF No. 81. On October 5, 2016, the Court entered an order granting in part and denying in part Cohen’s motion—specifically, the Court granted the motion as to Hi-Tech’s product disparagement and chapter 93A claims and denied it as to Hi-Tech’s defamation claim (but limited Hi-Tech’s recovery on that claim to special damages)—and denied Hi-Tech’s motion. Order, ECF No. 88. A jury trial on the surviving claims for libel and slander3 commenced on October 24, ' 2016;- Elec. Clerk’s Notes, ECF No. 99.

II. ANALYSIS

Summary judgment is proper “[w]hen the facts, so marshalled, show ‘that there is no genuine issue as to any material fact and that the moving party is entitled to a judgment as a matter of law[.]’ ” Mandel v. Boston Phoenix, Inc., 456 F.3d 198, 205 (1st Cir. 2006) (quoting Fed. R. Civ. P. 56(c)). The movant bears the burden of proving “an absence of evidence to support the nonmoving party’s case.” Clifford v. [243]*243Barnhart, 449 F.3d 276, 280 (1st Cir. 2006) (citing Celotex Corp. v. Catrett, 477 U.S. 317, 325, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986)).

Free access — add to your briefcase to read the full text and ask questions with AI

Hi-Tech Pharmaceuticals, Inc. v. Cohen, 277 F. Supp. 3d 236 (D. Mass. 2016).

277 F. Supp. 3d 236 (Hi-Tech Pharmaceuticals, Inc. v. Cohen) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related